Isolation and characterization of two newly established thymoma PDXs from two relapses of the same patient: a new tool to investigate thymic malignancies.
Patient-derived xenograft
Pre-clinical model
Thymoma
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
14 Dec 2022
14 Dec 2022
Historique:
received:
08
11
2022
accepted:
30
11
2022
entrez:
14
12
2022
pubmed:
15
12
2022
medline:
17
12
2022
Statut:
epublish
Résumé
Thymic malignancies are a heterogeneous group of rare cancers for which systemic chemotherapy is the standard treatment in the setting of advanced, recurrent or refractory diseases. Both environmental and genetic risk factors have not been fully clarified and few target-specific drugs have been developed for thymic epithelial tumors. A major challenge in studying thymic epithelial tumors is the lack of preclinical models for translational studies. Starting from bioptic material of two consecutive recurrences of the same patient, we generated two patient-derived xenografts. The patient-derived xenografts models were characterized for histology by immunohistochemistry and mutations using next-generation sequencing. When compared to the original tumors resected from the patient, the two patient-derived xenografts had preserved morphology after the stain with hematoxylin and eosin, although there was a moderate degree of de-differentiation. From a molecular point of view, the two patient-derived xenografts maintained 74.3 and 61.8% of the mutations present in the human tumor of origin. The newly generated patient-derived xenografts recapitulate both the molecular characteristics and the evolution of the thymoma it derives from well, allowing to address open questions for this rare cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Thymic malignancies are a heterogeneous group of rare cancers for which systemic chemotherapy is the standard treatment in the setting of advanced, recurrent or refractory diseases. Both environmental and genetic risk factors have not been fully clarified and few target-specific drugs have been developed for thymic epithelial tumors. A major challenge in studying thymic epithelial tumors is the lack of preclinical models for translational studies.
MAIN BODY
METHODS
Starting from bioptic material of two consecutive recurrences of the same patient, we generated two patient-derived xenografts. The patient-derived xenografts models were characterized for histology by immunohistochemistry and mutations using next-generation sequencing. When compared to the original tumors resected from the patient, the two patient-derived xenografts had preserved morphology after the stain with hematoxylin and eosin, although there was a moderate degree of de-differentiation. From a molecular point of view, the two patient-derived xenografts maintained 74.3 and 61.8% of the mutations present in the human tumor of origin.
SHORT CONCLUSION
CONCLUSIONS
The newly generated patient-derived xenografts recapitulate both the molecular characteristics and the evolution of the thymoma it derives from well, allowing to address open questions for this rare cancer.
Identifiants
pubmed: 36517829
doi: 10.1186/s13046-022-02554-4
pii: 10.1186/s13046-022-02554-4
pmc: PMC9749328
doi:
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
343Informations de copyright
© 2022. The Author(s).
Références
Virchows Arch. 2021 Jan;478(1):101-110
pubmed: 33674910
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Curr Opin Oncol. 2017 Mar;29(2):112-117
pubmed: 28027106
J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S260-5
pubmed: 20859116
BMC Bioinformatics. 2018 Oct 4;19(1):366
pubmed: 30286710
Nat Rev Cancer. 2017 Apr;17(4):254-268
pubmed: 28104906
Ann Oncol. 2015 May;26(5):838-847
pubmed: 25411417